Representative Ongoing Matters

In In re Foreign Exchange Antitrust Litigation, No. 13-cv-7789 (S.D.N.Y.), Nussbaum Law Group is co-lead Allocation Counsel for a sub-class of exchange-only foreign currency traders, who were victimized by the price-fixing scheme of sixteen of the world’s largest banks. The case is ongoing, but plaintiffs have already obtained court approval on settlements exceeding $2.3 billion.

In In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, MDL 1720 (E.D.N.Y.), Nussbaum Law Group is interim injunctive relief co-lead counsel for a proposed class of millions of merchants who accept Visa and Mastercard payment cards.

In In re Generic Pharmaceuticals Pricing Antitrust Litigation, MDL 2724 (E.D. Pa.), Nussbaum Law Group is on the Direct Purchaser Plaintiffs’ Steering Committee in the prosecution of class claims alleging wide-ranging price-fixing and market-rigging by multiple generic drug manufacturers. The case so far implicates nearly 20 different generic drugs.

In In re Liquid Aluminum Sulfate Antitrust Litigation, MDL 2687 (D. N.J.), Nussbaum Law Group is on the Direct Purchaser Plaintiffs’ Steering Committee in a case alleging bid rigging and overcharging by some of the country’s largest chemical manufacturers. The case is ongoing but the direct purchaser plaintiffs have already obtained settlements in excess of $50 million that are at various stages in the court approval process.

In First Impressions Salon, Inc., et al. v. National Milk Producers Federation, No. 13-cv-454 (S.D. Ill.), Nussbaum Law Group is part of the leadership team representing a certified class of purchasers against some of the country’s largest milk manufacturing co-operatives who, plaintiffs allege, unlawfully conspired to raise cheese and butter prices.

In In re Actos Direct Purchaser Antitrust Litigation¸ No. 15-cv-03278 (S.D.N.Y.), Nussbaum Law Group is a court-appointed interim co-lead class counsel for a proposed class of direct purchasers of Actos and Actoplus who allege they paid more for those products as a result of Defendants’ scheme to delay generic competition.

In In re Treasury Securities Auction Antitrust Litigation, MDL 2673 (S.D.N.Y.), Nussbaum Law Group represents various large treasury bond traders who allege that over two dozen of the world’s largest banks conspired to fix and manipulate the markets for a variety of debt instruments sold by the United States Department of Treasury.

In In re London Silver Fixing, Ltd. Antitrust Litigation, MDL 2573 (S.D.N.Y.), Nussbaum Law Group is part of the leadership team representing a proposed class of silver traders who allege that three of the world’s largest silver bullion banks conspired to fix silver prices via daily, non-public, and unregulated meetings.

In In re Packaged Seafood Products Antitrust Litigation, MDL 2670 (S.D. Cal.), Nussbaum Law Group represents direct action plaintiffs alleging that manufacturers of shelf-stable packaged tuna unlawfully colluded to unlawfully fix tuna prices.

 

Representative Settled Matters

In In re Celebrex (Celecoxib) Antitrust Litigation, No. 14-cv-00361 (E.D. Va.), Nussbaum Law Group was part of the leadership team representing a class of plaintiffs who purchased Celebrex directly from Pfizer, Inc. The plaintiffs alleged that Pfizer committed fraud so as to delay competition in the market for brand and generic versions of Celebrex. The class achieved a settlement of $94 million.

In Adriana M. Castro, M.D., P.A. v. Sanofi Pasteur Inc., No. 11-cv-07178 (D.N.J.), Nussbaum Law Group was co-lead counsel representing a class of nearly 30,000 medical practices, hospitals, and other healthcare providers who purchased Menactra, a quadrivalent meningococcal vaccine, directly from Sanofi Pasteur, Inc. The class alleged that Sanofi unlawfully monopolized this vaccine market to foreclose competition from other drug manufacturers. The class achieved a settlement of $61.5 million dollars.

In Axiom Investment Advisors, LLC v. Barclays Bank PLC, No. 15-cv-9323 (S.D.N.Y.), Nussbaum Law Group was part of the leadership team representing a class of plaintiffs bringing an action against Barclays Bank for its unlawful use of a “last look” algorithm that rejected and delayed certain foreign currency trades to the detriment of its customers. The class achieved a settlement of $50 million.